Key US Expert Group to Decide on Modifying Infant Hepatitis B Vaccine Recommendation
Following a hold-up and a particularly heated session, a national immunization advisory committee was scheduled to decide on Friday concerning altering the enduring advisory that all newborns be inoculated against hepatitis B.
Heated Debate and a Delayed Ballot
The opening session of the conference on Thursday was defined by heated debate over limiting availability to the hepatitis B vaccine for infants and a choice to postpone the decision by a day to give members more time to examine the language. The committee, which counsels the Centers for Disease Control and Prevention on vaccination protocols, had put off the vote twice in the past.
“Is there any definitive data of damage of giving this immunization before 30 days? Or is this speculation?” inquired one adviser.
In answer, another participant stated, “There is scant proof about the prolonged hazard.”
Existing Recommendations and Likely Ramifications
The vaccine is currently suggested for each baby within 24 hours of delivery to halt contraction of hepatitis B, which can result in serious liver damage. It has been administered to 1.4 billion people for in excess of thirty years.
The Georgia assembly offered no fresh data of damage attributable to the vaccine. Experts say any change to the existing hepatitis B immunization timeline could have major and extensive implications for infant and child health in the United States.
Panel Composition and New Appointments
The advisory panel can only offer guidance to the head of the CDC. The group's roster has experienced alterations recently, with the announcement that the group's former head would leave for an formal position and be succeeded by a cardiac doctor who has been skeptical about other inoculations.
The committee includes multiple vaccination critics who are in agreement with a aim to revamp – and potentially, in some cases, scrap – traditional vaccination recommendations.
